Risks and benefits of bone marrow transplantation in children
Overview of Bone Marrow Transplantation
- Hematopoietic stem cell transplantation (HSCT) utilizes either allogeneic (donor-derived) or autologous (patient-derived) stem cells to treat various malignant and nonmalignant disorders.
- Autologous transplantation serves as a rescue strategy after delivering lethal doses of chemotherapy and/or radiotherapy.
- Allogeneic transplantation is utilized to treat genetic diseases of blood cells, primary immunodeficiencies, inherited metabolic diseases, and hematologic malignancies.
- The conditioning regimen serves to eliminate the patient's existing hematopoietic system, suppress the immune system to prevent rejection, and significantly reduce the tumor burden.
- The infused graft contains mature donor blood cells (T cells, B cells, natural killer cells, dendritic cells) that establish a new immune system.
- This new immune system provides a critical graft-versus-leukemia (GVL) effect, eliminating residual malignant cells.
Benefits: Clinical Indications and Curative Potential
The primary benefit of HSCT is its ability to offer a definitive, life-saving cure for conditions that are otherwise rapidly fatal or associated with severe lifelong morbidity.
| Disease Category | Specific Disorders | Expected Benefit and Survival Outcomes |
|---|---|---|
| Hematologic Malignancies | Acute Lymphoblastic Leukemia (ALL) | Yields 70-80% 3-year overall survival (OS) in high-risk first or second complete remission. |
| Acute Myeloid Leukemia (AML) | Provides better event-free survival than chemotherapy alone for high-risk patients, yielding 60-70% OS. | |
| Chronic Myelogenous Leukemia (CML) | Offers leukemia-free survival of 45-80%, utilized primarily for patients intolerant to tyrosine kinase inhibitors. | |
| Juvenile Myelomonocytic Leukemia (JMML) | Cures approximately 50-60% of patients with this aggressive malignancy. | |
| Lymphomas and Solid Tumors | Autologous HSCT rescues relapsed Hodgkin and non-Hodgkin lymphomas (50-60% event-free survival) and high-risk neuroblastomas. | |
| Primary Immunodeficiencies | Severe Combined Immunodeficiency (SCID) | Provides a definitive cure, with survival approaching 95% when performed optimally in the first 100 days of life. |
| Wiskott-Aldrich, LAD, CGD | Curative treatment; survival approaches 100% with an HLA-identical sibling donor. | |
| Inherited Bone Marrow Failure | Fanconi Anemia, Aplastic Anemia | Rescues bone marrow failure and prevents clonal hematopoiesis. Achieves >90% 5-year OS in Fanconi anemia; >80% long-term survival in severe aplastic anemia. |
| Hemoglobinopathies | Thalassemia Major | Offers >90% probability of survival with complete transfusion independence in patients without severe liver damage. |
| Sickle Cell Disease | Curative for patients with recurrent vasoocclusive crises or strokes, offering an 80-90% probability of cure. | |
| Metabolic Diseases | Hurler Syndrome, Adrenoleukodystrophy | Engrafts microglial cells that deliver necessary enzymes to the central nervous system, preventing irreversible neurologic damage. |
Early Risks and Complications
Acute Graft-Versus-Host Disease (GVHD)
- Acute GVHD is a major cause of mortality and morbidity following allogeneic HSCT.
- The disease is caused by alloreactive donor T cells attacking recipient tissues.
- Significant acute GVHD develops in approximately 30% of matched sibling recipients and up to 60% of unrelated donor recipients.
- It typically manifests within the first 2 to 8 weeks post-transplant.
- Target organs include the skin (maculopapular rash), liver (elevated bilirubin and transaminases), and gastrointestinal tract (anorexia, vomiting, severe diarrhea).
- Severe multiorgan disease (Grade IV) is a life-threatening and frequently fatal condition.
Infectious Complications
- HSCT recipients experience a transient but profound state of immune deficiency.
- During the pre-engraftment phase, severe neutropenia and mucositis render patients highly susceptible to bacterial sepsis (enteric gram-negative bacilli) and invasive fungal diseases (Candida, Aspergillus).
- In the post-engraftment phase, delayed cellular recovery predisposes patients to severe viral infections.
- Cytomegalovirus (CMV) infection is a frequent complication, and CMV pneumonia carries a case fatality rate of 85% in the absence of early treatment.
- Epstein-Barr virus (EBV) reactivation can lead to post-transplant lymphoproliferative disease (PTLD).
- Disseminated adenovirus infection can cause fatal hepatitis, enteritis, and pneumonia in recipients of T-cell-depleted grafts.
Graft Failure and Rejection
- Graft failure exposes patients to a high risk of fatal infection.
- Primary graft failure is defined as the failure to achieve a neutrophil count of 0.5 x 10^9/L.
- Secondary graft failure is the loss of peripheral blood counts after initial engraftment.
- Immune-mediated rejection occurs when residual host T-lymphocytes survive the conditioning regimen and reject the donor cells.
- The risk is highest in HLA-disparate transplants, T-cell-depleted grafts, and when utilizing reduced-intensity conditioning regimens.
Venoocclusive Disease (VOD)
- Also known as sinusoidal obstruction syndrome, VOD results from conditioning-induced endothelial damage to the liver.
- It typically presents within 30 days of transplantation.
- Clinical features include massive hepatomegaly, jaundice, fluid retention, and ascites.
- The severe form of VOD has a mortality rate exceeding 80% without appropriate treatment with agents like defibrotide.
Long-Term Risks and Late Complications
As supportive care improves, a growing number of pediatric patients become long-term survivors, facing risks from previous therapies.
| Organ System | Late Effect or Complication |
|---|---|
| Immunologic | Chronic graft-versus-host disease (GVHD), prolonged immunodeficiency. |
| Endocrine | Growth impairment, growth hormone deficiency, primary ovarian or testicular failure, delayed puberty, infertility, hypothyroidism. |
| Cardiovascular | Metabolic syndrome (dyslipidemia, hypertension, diabetes mellitus), cardiomyopathy, atherosclerosis. |
| Oncologic | Secondary malignancies (myelodysplastic syndrome, secondary leukemia, thyroid carcinoma, brain tumors). |
| Neurologic | Neurocognitive deficits, leukoencephalopathy (especially with prior cranial radiation or TBI). |
| Other Systems | Restrictive pulmonary fibrosis, renal toxicity, cataracts, dental abnormalities, osteoporosis, avascular necrosis. |
Chronic Graft-Versus-Host Disease
- Chronic GVHD is the major cause of nonrelapse mortality and morbidity in long-term HSCT survivors.
- The incidence in pediatric patients is approximately 25%.
- It functions as a systemic disorder of immune regulation, producing autoimmune-like symptoms.
- Manifestations include scleroderma, sicca syndrome, progressive bronchiolitis obliterans, chronic diarrhea, and cirrhosis.
- Chronic GVHD requires continuous immunosuppressive therapy for 1 to 3 years, prolonging susceptibility to opportunistic infections.
Endocrine and Growth Impairment
- Children given HSCT before puberty may develop severe growth impairment, precluding achievement of normal adult height.
- Total body irradiation causes direct damage to cartilage plates and the hypothalamic-pituitary axis, leading to growth hormone deficiency.
- Patients receiving TBI or high doses of alkylating agents frequently experience primary gonadal failure, resulting in delayed puberty and a high risk of permanent infertility.
Secondary Malignancies
- The overall risk of developing a secondary cancer is significantly higher after HSCT than in the general population.
- The most frequently diagnosed neoplasms include myelodysplastic syndromes, secondary acute leukemias, thyroid carcinoma, brain tumors, and epithelial cancers.
- Risk factors include the use of total body irradiation, chronic GVHD, and an intrinsic genetic predisposition (e.g., Fanconi anemia).